Click Essential only to reject non-essential cookies, or Close to continue without changing your preferences
Acta Histochemica, 116(1), 61-69
Clinical data from the SUSTAIN and STEP trials show that participants who stopped semaglutide regained approximately two-thirds of lost weight within one year
The difference lies in manufacturing and delivery: brand-name versions use proprietary devices and include higher overhead costs, while PlexusDx sources compounded semaglutide from licensed 503A pharmacies using standard injection equipment, reducing expense without compromising the medication's chemical efficacy
Kepka A, Ochocinska A, Borzym-Kluczyk M, Skorupa E, Stasiewicz-Jarocka B, Chojnowska S, et al